In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
-
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
-
REGULATORY FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
-
BUSINESS Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
-
BUSINESS Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th
October 3, 2011
-
ORGANIZATION Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
-
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
-
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
-
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
-
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
-
BUSINESS MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
-
ORGANIZATION JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
-
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
-
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
-
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
-
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
-
BUSINESS Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
-
BUSINESS Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
-
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
-
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…